A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

NCT06485219 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Cutaneous T-cell Lymphoma (CTCL)

Interventions

DRUG: 11.2 mg/m2 Purinostat Mesylate
DRUG: 15 mg/m2 Purinostat Mesylate

Sponsor

Chengdu Zenitar Biomedical Technology Co., Ltd